The corresponding relative risk reduction is quite dependent on the tumor biology than around the nodal position and extent of disease [62]. In case of pT2 pN0 a taxane centered polychemotherapy additionally trastuzumab monotherapy is suggested which could be followed in the event of a HR+ tumor by neratinib https://frankf107biq4.life-wiki.com/user